MORRISVILLE, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global contract research organization (CRO) announced that researchers Melissa (Missy) Vadnais, V.M.D, Ph.D., Fellow, Clinical Research Methodology, and Laura Ziznewski, Ph.D., Fellow, Clinical Research Methodology, have joined the Michael F. Murphy Clinical Research Methodology Fellowship Program.
As part of the company’s commitment to providing customers value through innovative study and program design, the competitive, two-year fellowship program was established in 2017 to prepare scientists and physician researchers who will support the increasingly complex clinical trials of tomorrow. With a 30 year career based in the integration of therapeutic acumen with operational excellence, Michael Murphy, M.D., Ph.D., chief medical and scientific officer for Worldwide, will continue to guide the fellows through the program. They’ll be exposed to the industry’s top experts across all phases of development, in multiple therapeutic areas and phases, including central nervous system (CNS), oncology, rare and orphan diseases, cardiovascular, and general medicine.
“Our fellowship program is particularly exciting because it is emblematic of the vision of the company, which, from its inception, has been based on methodological rigor linked to impeccable operational acumen,” said Dr. Murphy. “Increasingly, the current R&D space demands informed, differentiated services under an umbrella that complements the contributions of employees, patients, families and investigative sites. Our fellowship program bridges all of these worlds through didactic and experiential learning, providing training and mentoring for individuals who will contribute to the future of clinical research.”
The contributions of Worldwide’s previous fellows, William Slone, Ph.D., and deMauri Mackie, Ph.D., have been unparalleled as they have transitioned from top-tier bench scientists to join some of the most methodologically adept individuals within the clinical CRO space. Characterized by passion and purpose, both have supported a wide range of activities at Worldwide during their tenure. Contributions span the development of strategic programs for interventional research, developing protocol concepts, exploring the possibilities of innovative study methodology, and providing public presentations accentuating the transformative nature of current drug development opportunities at events like Women in Bio and NORD Summit. Importantly, the Fellowship program places a premium on “hands on deliverables” with the content and milestone challenges associated with those initiatives. Formal rotations across functional areas within the Worldwide organization provide an essential element to the training program. The company rotations create an exceptional opportunity to build cross-departmental relationships, essential competencies for differentiated services.
Vadnais and Ziznewski stood out as exemplary candidates among more than 50 applicants. Vadnais, who is both a veterinarian and a cellular and molecular biologist by training, has more than 15 years of experience in medicine and science. “I have always been very focused on translational medicine and drug development,” said Vadnais. “I’ve had the opportunity to work with regulatory bodies and CROs in both the veterinary and human side of things. I truly wanted to be a part of that world and learn from the best.”
Ziznewski is a neuroscientist who studied both behavioral neuroscience and behavioral pharmacology and has 10 years of scientific experience. “I was attracted to the fellowship opportunity with Worldwide because I would be learning directly through Dr. Murphy, one of the best in the industry, and thanks to the rotations, I felt it was a way to learn, hands-on, everything I could about the clinical research business,” said Ziznewski.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,700 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO.
For more information, visit http://www.worldwide.com.